FGF2 as a potential prognostic biomarker for proneural glioma patients

Authors

  • Linda Sooman Department of Radiology, Oncology and Radiation Sciences, Section of Oncology, Rudbeck Laboratory, Uppsala, Sweden
  • Eva Freyhult Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Science for Life Laboratory, Bioinformatics Infrastructure for Life Sciences, Uppsala University, Uppsala, Sweden
  • Archita Jaiswal Lab Surgpath, The Human Protein Atlas Project, Mumbai Site, Mumbai, India
  • Sanjay Navani Lab Surgpath, The Human Protein Atlas Project, Mumbai Site, Mumbai, India
  • Per-Henrik Edqvist Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
  • Fredrik Pontén Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
  • Elena Tchougounova Department of Immunology, Genetics and Pathology, Section of Cancer and Vascular Biology, Rudbeck Laboratory, Uppsala, Sweden
  • Anja Smits Department of Neuroscience, Section of Neurology, Uppsala University Hospital, Uppsala, Sweden
  • Tamador Elsir Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
  • Joachim Gullbo Department of Radiology, Oncology and Radiation Sciences, Section of Oncology, Rudbeck Laboratory, Uppsala, Sweden; Department of Medical Sciences, Section of Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
  • Johan Lennartsson Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden
  • Michael Bergqvist Department of Radiology, Oncology and Radiation Sciences, Section of Oncology, Rudbeck Laboratory, Uppsala, Sweden
  • Simon Ekman Department of Radiology, Oncology and Radiation Sciences, Section of Oncology, Rudbeck Laboratory, Uppsala, Sweden

DOI:

https://doi.org/10.3109/0284186X.2014.951492

Abstract

Background. The survival of high-grade glioma patients is poor and the treatment of these patients can cause severe side effects. This fosters the necessity to identify prognostic biomarkers, in order to optimize treatment and diminish unnecessary suffering of patients. The aim of this study was to identify prognostic biomarkers for high-grade glioma patients.

Methods. Eleven proteins were selected for analysis due to their suggested importance for survival of patients with other types of cancers and due to a high variation in protein levels between glioma patients (according to the Human Protein Atlas, www.proteinatlas.org). Protein expression patterns of these 11 proteins were analyzed by immunohistochemistry in tumor samples from 97 high-grade glioma patients. The prognostic values of the proteins were analyzed with univariate and multivariate Cox regression analyses for the high-grade glioma patients, including subgroup analyses of histological subtypes and immunohistochemically defined molecular subtypes.

Results. The proteins with the most significant (univariate and multivariate p < 0.05) correlations were analyzed further with cross-validated Kaplan-Meier analyses for the possibility of predicting survival based on the protein expression pattern of the corresponding candidate. Random Forest classification with variable subset selection was used to analyze if a protein signature consisting of any combination of the 11 proteins could predict survival for the high-grade glioma patients and the subgroup with glioblastoma patients. The proteins which correlated most significantly (univariate and multivariate p < 0.05) to survival in the Cox regression analyses were Myc for all high-grade gliomas and FGF2, CA9 and CD44 for the subgroup of proneural gliomas, with FGF2 having a strong negative predictive value for survival. No prognostic signature of the proteins could be found.

Conclusion. FGF2 is a potential prognostic biomarker for proneural glioma patients, and warrants further investigation.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2015-03-16

How to Cite

Sooman, L., Freyhult, E., Jaiswal, A., Navani, S., Edqvist, P.-H., Pontén, F., … Ekman, S. (2015). FGF2 as a potential prognostic biomarker for proneural glioma patients. Acta Oncologica, 54(3), 385–394. https://doi.org/10.3109/0284186X.2014.951492

Issue

Vol. 54 No. 3 (2015): Acta Oncologica

Section

Articles